In bladder cancer, the tumor-associated dendritic cells were found to secrete CXCL9, increasing PD-L1 expression in the tumor cells via the CXCR3/STAT3/AKT signaling pathway, thus resulting in the inhibition of anti-tumor adaptive immunity (163). Here, CXCL9 is linked to urinary bladder cancer.